An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's natural history, its burden on patients and their families, its treatment, as well as its medical, social and pharmacoeconomic impact.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in EuroQol 5-dimension 5-level (EQ-5D-5L) score
Timeframe: Monthly throughout 2 year study duration
Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score
Timeframe: Four times per six months throughout 2 year study duration
Change in Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL15r) score
Timeframe: Once per six months throughout 2 year study duration
Change in Hospital Anxiety and Depression Scale (HADS) score
Timeframe: Once per six months throughout 2 year study duration
Change in Health Utilities Index III (HUI3) score
Timeframe: Once per 12 months throughout 2 year study duration
COVID-19 survey results
Timeframe: Monthly throughout 2 year study duration
Change in Single Simple Question (SSQ) and Patient Acceptable Symptom States (PASS) scores
Timeframe: Four times per six months throughout 2 year study duration
Change in EuroQol 5-dimension 3-level (EQ-5D-3L) score
Timeframe: Monthly for three months for participants from the US and Italy only